Summary | |
---|---|
Symbol | PVR |
Name | poliovirus receptor |
Aliases | CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Isoform Alpha: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform Delta: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform Beta: Secreted.; SUBCELLULAR LOCATION: Isoform Gamma: Secreted. |
Domain |
PF08205 CD80-like C2-set immunoglobulin domain PF07686 Immunoglobulin V-set domain |
Function |
Mediates NK cell adhesion and triggers NK cell effector functions. Binds two different NK cell receptors: CD96 and CD226. These interactions accumulates at the cell-cell contact site, leading to the formation of a mature immunological synapse between NK cell and target cell. This may trigger adhesion and secretion of lytic granules and IFN-gamma and activate cytoxicity of activated NK cells. May also promote NK cell-target cell modular exchange, and PVR transfer to the NK cell. This transfer is more important in some tumor cells expressing a lot of PVR, and may trigger fratricide NK cell activation, providing tumors with a mechanism of immunoevasion. Plays a role in mediating tumor cell invasion and migration. ; FUNCTION: (Microbial infection) Acts as a receptor for poliovirus. May play a role in axonal transport of poliovirus, by targeting virion-PVR-containing endocytic vesicles to the microtubular network through interaction with DYNLT1. This interaction would drive the virus-containing vesicle to the axonal retrograde transport. ; FUNCTION: (Microbial infection) Acts as a receptor for Pseudorabies virus. ; FUNCTION: (Microbial infection) Is prevented to reach cell surface upon infection by Human cytomegalovirus /HHV-5, presumably to escape immune recognition of infected cell by NK cells. |
Biological Process |
GO:0001906 cell killing GO:0001909 leukocyte mediated cytotoxicity GO:0001910 regulation of leukocyte mediated cytotoxicity GO:0001912 positive regulation of leukocyte mediated cytotoxicity GO:0001913 T cell mediated cytotoxicity GO:0001914 regulation of T cell mediated cytotoxicity GO:0001916 positive regulation of T cell mediated cytotoxicity GO:0002228 natural killer cell mediated immunity GO:0002250 adaptive immune response GO:0002347 response to tumor cell GO:0002418 immune response to tumor cell GO:0002420 natural killer cell mediated cytotoxicity directed against tumor cell target GO:0002423 natural killer cell mediated immune response to tumor cell GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002456 T cell mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002697 regulation of immune effector process GO:0002699 positive regulation of immune effector process GO:0002703 regulation of leukocyte mediated immunity GO:0002705 positive regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002708 positive regulation of lymphocyte mediated immunity GO:0002709 regulation of T cell mediated immunity GO:0002711 positive regulation of T cell mediated immunity GO:0002715 regulation of natural killer cell mediated immunity GO:0002717 positive regulation of natural killer cell mediated immunity GO:0002819 regulation of adaptive immune response GO:0002821 positive regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002831 regulation of response to biotic stimulus GO:0002833 positive regulation of response to biotic stimulus GO:0002834 regulation of response to tumor cell GO:0002836 positive regulation of response to tumor cell GO:0002837 regulation of immune response to tumor cell GO:0002839 positive regulation of immune response to tumor cell GO:0002855 regulation of natural killer cell mediated immune response to tumor cell GO:0002857 positive regulation of natural killer cell mediated immune response to tumor cell GO:0002858 regulation of natural killer cell mediated cytotoxicity directed against tumor cell target GO:0002860 positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0008037 cell recognition GO:0019058 viral life cycle GO:0030260 entry into host cell GO:0031341 regulation of cell killing GO:0031343 positive regulation of cell killing GO:0031349 positive regulation of defense response GO:0034330 cell junction organization GO:0034332 adherens junction organization GO:0042267 natural killer cell mediated cytotoxicity GO:0042269 regulation of natural killer cell mediated cytotoxicity GO:0042271 susceptibility to natural killer cell mediated cytotoxicity GO:0044409 entry into host GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045216 cell-cell junction organization GO:0045954 positive regulation of natural killer cell mediated cytotoxicity GO:0046718 viral entry into host cell GO:0051701 interaction with host GO:0051806 entry into cell of other organism involved in symbiotic interaction GO:0051828 entry into other organism involved in symbiotic interaction GO:0060370 susceptibility to T cell mediated cytotoxicity GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules |
Molecular Function |
GO:0001618 virus receptor activity GO:0050839 cell adhesion molecule binding |
Cellular Component |
GO:0005913 cell-cell adherens junction GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0030055 cell-substrate junction |
KEGG |
hsa04514 Cell adhesion molecules (CAMs) |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-418990: Adherens junctions interactions R-HSA-446728: Cell junction organization R-HSA-1500931: Cell-Cell communication R-HSA-421270: Cell-cell junction organization R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell R-HSA-420597: Nectin/Necl trans heterodimerization |
Summary | |
---|---|
Symbol | PVR |
Name | poliovirus receptor |
Aliases | CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between PVR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between PVR and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | PVR |
Name | poliovirus receptor |
Aliases | CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of PVR in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | PVR |
Name | poliovirus receptor |
Aliases | CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of PVR in various data sets.
|
Points in the above scatter plot represent the mutation difference of PVR in various data sets.
|
Summary | |
---|---|
Symbol | PVR |
Name | poliovirus receptor |
Aliases | CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PVR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | PVR |
Name | poliovirus receptor |
Aliases | CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PVR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PVR. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | PVR |
Name | poliovirus receptor |
Aliases | CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PVR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | PVR |
Name | poliovirus receptor |
Aliases | CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of PVR expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | PVR |
Name | poliovirus receptor |
Aliases | CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between PVR and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | PVR |
Name | poliovirus receptor |
Aliases | CD155; HVED; Necl-5; NECL5; Tage4; nectin-like 5; PVS; nectin-like protein 5; CD antigen CD155 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting PVR collected from DrugBank database. |
Details on drugs targeting PVR.
|